Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis.

Breast cancer research and treatment - 1 Sept 2023

Rosin Justus, Svegrup Ella, Valachis Antonios, Zerdes Ioannis

Abstract excerpt

INTRODUCTION: In light of the clinically meaningful results of the PI3K inhibitors in PIK3CA-mutated metastatic breast cancer (BC) patients, the reliable identification of PIK3CA mutations is of outmost importance. However, lack of evidence on the optimal site and timing of assessment, presence of temporal heterogeneity and analytical factors pose several challenges in clinical routine. We aimed to study the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Phosphatidylinositol 3-Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 37392328
DOI: 10.1007/s10549-023-07010-1
PMCID: PMC10361863

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis.PMID 37392328Read ↗

Discordance of PIK3CA and TP53 Mutations Between Breast Cancer Brain Metastases and Matched Primary TumorsSemantic proximity Read ↗

Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors.Semantic proximity Read ↗

Analysis of PIK3CA mutations in the primary and recurrent tumors of hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancer.Semantic proximity Read ↗

Analysis of PIK3CA Mutation Concordance and Frequency in Primary and Different Distant Metastatic Sites in Breast Cancer.Semantic proximity Read ↗

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.Semantic proximity Read ↗

Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast CancerSemantic proximity Read ↗

PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories.Semantic proximity Read ↗

PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.Semantic proximity Read ↗

Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.Semantic proximity Read ↗

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.Semantic proximity Read ↗

Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus.Semantic proximity Read ↗

PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.